---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-002800"
form_type: "8-K"
ticker: "OSUR"
cik: "0001116463"
company_name: "ORASURE TECHNOLOGIES INC"
filed_at: "2023-02-14T23:59:59+00:00"
generated_at: "2026-06-19T13:08:19.834224+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# OraSure Q4 revenue record $123.1M (+94% YoY); GAAP EPS $0.21; restructuring cuts 11% of workforce

## Summary
- Q4 revenue $123.1M record (+94% YoY); InteliSwab $88.9M (+502% YoY, +12% sequential).
- GAAP EPS $0.21, non-GAAP EPS $0.36; full-year GAAP EPS ($0.25), non-GAAP $0.34.
- Restructuring combines Molecular & Diagnostics units; 11% non-production role cuts, $15M annual savings by June 2023.
- Cash $110.8M, up $9M QoQ; guides Q1 revenue $125–130M (85–92% YoY growth).
- New federal InteliSwab contracts through Nov 2023; deal with Quest for saliva collection kits.

## SEC filing metadata
- accession: 0000950170-23-002800
- form_type: 8-K
- ticker: OSUR
- cik: 0001116463
- company_name: ORASURE TECHNOLOGIES INC
- filed_at: 2023-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1116463/000095017023002800/0000950170-23-002800-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1116463/000095017023002800/osur-20230214.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-002800
- JSON: https://secwatch.observer/filing/0000950170-23-002800.json
- Plain text: https://secwatch.observer/filing/0000950170-23-002800.txt

## Key facts
- Earnings Releases
  ORASURE TECHNOLOGIES INC reported Q4 2022 results: revenue $123,078, net income 15,561, EPS $0.21.
  - Period: Q4 2022
  - Revenue: $123,078
  - Net income: 15,561
  - EPS: $0.21
  - Result: reported results
  source text: Financial Highlights Three Months Ended Year Ended December 31, December 31, 2022 2021 % Change 2022 2021 % Change Core Diagnostics $ 18,400 $ 17,898 3 % $ 70,007 $ 67,333 4 % InteliSwab 88,857 14,770 502 233,666 22,707 929 Total Diagnostics 107,257 32,668 228 303,673 90,040 237 Core Molecular Solutions 15,684 22,936 (32 ) 74,147 89,467 (17 ) COVID-19 kits 137 7,964 (98 ) 9,659 54,167 (82 ) Total Molecular Solutions 15,821 30,900 (49 ) 83,806 143,634 (42 ) Total Revenue $ 123,078 $ 63,568 94 % $ 387,479 $ 233,674 66 % Three Months Ended Year ended December 31, December 31, 2022 2021 % Change 2022 2021 % Change Net revenues $ 123,078 $ 63,568 94 % $ 387,479 $ 233,674 66 % Gross profit 49,589 27,133 83 147,637 117,600 26 Gross margin 40 % 43 % 38 % 50 % Non-GAAP gross profit 50,126 28,685 75 154,464 121,708 27 Non-GAAP gross margin 41 % 45 % 40 % 52 % Operating income (loss) 13,435 (9,371 ) NM (22,957 ) (10,164 ) NM Operating margin 11 % -15 % -6 % -4 % Non-GAAP operating income (loss) 1
  evidence_url: https://www.sec.gov/Archives/edgar/data/1116463/000095017023002800/0000950170-23-002800-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.